SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at the Morgan Stanley Global
Healthcare Conference on Wednesday, May 2, 2007 at 9:30 a.m. ET in Miami.
Daniel M. Bradbury, President and Chief Executive Officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
through Amylin's corporate website, located at http://www.amylin.com. To access
the live webcast, please log on to Amylin's site approximately fifteen
minutes prior to the presentation to register and download any necessary
audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,600 employees nationwide. For
more information about Amylin visit http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Alice Bahner, Executive Director, Investor
Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext.
7272
|
